An overview of the efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC patients with EGFR mutation. We also focused on the mechanisms that affect the efficacy of ICIs in patients with EGFR mutation and further investigation worth to be done in future.

In recent years, immunotherapy has been considered the most promising method to overcome cancer and extend survival. It has been widely reported in preclinical and clinical studies that radiotherapy induces immunomodulatory effects by releasing TAAs and activating immunoregulation-related signaling pathways, initiating tumor-specific cytotoxic T cells, and promoting T cells to enter into tumor tissues. In this manuscript, we summarize the current status of immunotherapy and iRT and the development and additional combination strategies to enhance the efficacy of iRT.

We reported the dual function of LINC00525 in fine-tuning p21 production at both the transcriptional and post-transcriptional levels. We suggest that LINC00525 may represent a potential therapeutic target for clinical intervention in lung adenocarcinoma.

This study demonstrated similarity between LY01008 and reference bevacizumab (Avastin) in terms of efficacy, safety, and immunogenicity in combination with paclitaxel and carboplatin as first-line treatment in Chinese patients with advanced non-squamous NSCLC.

In this study, a novel cell cycle regulator named meiotic nuclear divisions 1 (MND1) was firstly screened out as a potential oncogene in LUAD using different bioinformatic and statistical analyses. In mechanism, MND1 could directly bind to tumor suppressor kruppel-like factor 6 (KLF6) to protect E2F1 from the transcriptional repression of KLF6. Interestingly, in return, E2F1 could activate MND1 transcription by binding to a specific site in the promoter region of MND1.

Tepotinib have high retention in the tumor and sustained inhibition of MET and its downstream pathways. Tepotinib is a key drug for cancer patients with MET exon 14 skipping mutation. However, its bioavailability in the CSF in humans has not been elucidated. The blood brain barrier protects the CNS from toxicity, but also prevents therapeutic drugs from accessing the brain. We report a case of leptomeningeal metastasis successfully treated with tepotinib in a patient with poor PS and on the bioavailability of tepotinib in the CSF in humans.